The compass study

Rivaroxaban significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patient with chronic coronary or peripheral artery disease by 24%

  • Important relative risk reduction in stroke (42%) and in cardiovascular death (22%) was induced by rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100mg once daily compared with aspirin 100mg once daily alone
  • While major bleeding was increased, there was no significant increase in intracranial or fatal bleeding (bleeding rates were low)
  • The combination regimen indicates a significant improvement in net clinical benefit of 20%

< Return